SCM
PTGX icon

Sio Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Sio Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-460,044
Closed -$10.5M – 56
2023
Q4 		$10.5M Buy
460,044
+211,917
+85% +$3.71M 2.4% 12
2023
Q3 		$4.14M Buy
+248,127
New +$4.81M 1.28% 23
2023
Q1 		– Sell
-434,635
Closed -$4.74M – 52
2022
Q4 		$4.74M Buy
+434,635
New +$3.67M 1.75% 15
2021
Q4 		– Sell
-90,000
Closed -$1.59M – 77
2021
Q3 		$1.59M Buy
+90,000
New +$3.84M 0.51% 47

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Sio Capital Management's PTGX Position: Q1 2024 in Review

Sio Capital Management sold out of Protagonist Therapeutics (PTGX) in Q1 2024, closing a stake of 460,044 shares — an estimated $10.5M sold.

Sio Capital Management first reported a position in PTGX in Q3 2021 and held it in 4 quarters. The position peaked at $10.5M in Q4 2023. 184 funds tracked by Wall St. Rank hold PTGX as of Q1 2024.

  • Sio Capital Management reported no remaining Protagonist Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Sio Capital Management sold 460,044 Protagonist Therapeutics shares in Q1 2024, an estimated $10.5M.
  • Sio Capital Management first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 4 quarters.
  • Sio Capital Management's Protagonist Therapeutics position peaked at $10.5M in Q4 2023.
  • 184 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2024.

Based on Sio Capital Management's 13F filing for Q1 2024, filed 15 May 2024.